ରେମିମାଜୋଲାମ

ରେମିମାଜୋଲାମ
Clinical data
Trade names	Byfavo
Synonyms	Remimazolam besylate, CNS-7056
AHFS/Drugs.com	monograph
data	EU EMA: yes; US DailyMed: Remimazolam;
Routes of; administration	Intravenous
Legal status
Legal status	CA: Schedule IV ; DE: Anlage III (Prescription only) ; UK: PSA ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Duration of action	10 min
Identifiers
	IUPAC name methyl 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate;
Chemical and physical data
Formula	C21H19BrN4O2
Molar mass	୪୩୯.୩୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21;
	InChI InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1 ; Key:CYHWMBVXXDIZNZ-KRWDZBQOSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Remimazolam

ରେମିମାଜୋଲାମ (ଇଂରାଜୀ ଭାଷାରେ Remimazolam), ଏକ ବେପାର ନାମ ବାଇଫାଭୋ, ହେଉଛି ପ୍ରୋସିଡୁରାଲ ସେଡେସନ (procedural sedation) ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୨] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ୩୦ମିନିଟରୁ କମ୍ ଚାଲିଥିବା ପ୍ରଣାଳୀ ପାଇଁ ବୟସ୍କମାନଙ୍କ କ୍ଷେତ୍ରରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୨] ପ୍ରଭାବର ଆରମ୍ଭ ସମାନ ଥିବାବେଳେ ମିଡିଜୋଲାମ ଅପେକ୍ଷା ଏହାର ଅବଧି କମ ଅଟେ ।^[୫] ^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମ୍ନ ରକ୍ତଚାପ, ଉଚ୍ଚ ରକ୍ତଚାପ ଏବଂ କମ୍ ଅମ୍ଳଜାନ ହୋଇପାରେ ।^[୨] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅପବ୍ୟବହାର ଏବଂ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ ।^[୨] ବୃକ୍‌କ ସମସ୍ୟାରେ ଫଳାଫଳର ପରିବର୍ତ୍ତନ ହୁଏ ନାହିଁ, ଯଦିଓ ଯକୃତ ଜନିତ ସମସ୍ୟାରେ କମ ମାତ୍ରାରେ ବ୍ୟବହାର କରାଯାଇପାରେ ।^[୨] ^[୭] ଏହାର ପ୍ରଭାବକୁ ଫ୍ଲୁମାଜେନିଲ ଦେଇ ଓଲଟାଇ ଦିଆଯାଇପାରେ ।^[୪] ଏହା ଏକ ବେଞ୍ଜୋଡାଏଜେପିନ୍ ଯାହା ଗାମା-ଆମିନୋ ବ୍ୟୁଟିରିକ ଏସିଡ (GABA) ରିସେପ୍ଟର ସହିତ ସଂଲଗ୍ନ ହୋଇ କାର୍ଯ୍ୟ କରେ ।^[୩]

ରେମିମାଜୋଲାମକୁ ୨୦୨୦ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୧ରେ ୟୁରୋପରେ ଚିକିତ୍ସା ପାଇଁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୨] ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ମିଗ୍ରା ବିଶିଷ୍ଟ ଏକ ପାତ୍ରର ମୂଲ୍ୟ ପ୍ରାୟ ୪୨ ଡଲାର ଅଟେ ।^[୮]

ଆଧାର

↑ Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. (2007). "CNS 7056: a novel ultra-short-acting Benzodiazepine". Anesthesiology. 107 (1): 60–6. doi:10.1097/01.anes.0000267503.85085.c0. PMID 17585216. S2CID 19504961.
1 2 3 4 5 6 7 8 "Byfavo- remimazolam besylate injection, powder, lyophilized, for solution". DailyMed. 20 July 2020. Archived from the original on 22 October 2022. Retrieved 25 February 2021.
1 2 3 "Byfavo EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 21 April 2021. Retrieved 20 April 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1 2 Kaye, Alan David (5 June 2017). Pharmacology, An Issue of Anesthesiology Clinics (in ଇଂରାଜୀ). Elsevier Health Sciences. p. e101. ISBN 978-0-323-52998-3. Archived from the original on 12 November 2022. Retrieved 3 November 2022.
↑ Noor, N; Legendre, R; Cloutet, A; Chitneni, A; Varrassi, G; Kaye, AD (2021). "A comprehensive review of remimazolam for sedation". Health psychology research. 9 (1): 24514. doi:10.52965/001c.24514. PMID 34746482.
↑ Goudra, BG; Singh, PM (July 2014). "Remimazolam: The future of its sedative potential". Saudi journal of anaesthesia. 8 (3): 388–91. doi:10.4103/1658-354X.136627. PMID 25191193.{{cite journal}}: CS1 maint: unflagged free DOI (link)
↑ "Remimazolam Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 3 November 2022.
↑ "Byfavo Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 May 2022. Retrieved 3 November 2022.

[1] Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. (2007). "CNS 7056: a novel ultra-short-acting Benzodiazepine". Anesthesiology. 107 (1): 60–6. doi:10.1097/01.anes.0000267503.85085.c0. PMID 17585216. S2CID 19504961.

[PI2022-2] 1 2 3 4 5 6 7 8 "Byfavo- remimazolam besylate injection, powder, lyophilized, for solution". DailyMed. 20 July 2020. Archived from the original on 22 October 2022. Retrieved 25 February 2021.

[EPAR2022-3] 1 2 3 "Byfavo EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 21 April 2021. Retrieved 20 April 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Kay2017-4] 1 2 Kaye, Alan David (5 June 2017). Pharmacology, An Issue of Anesthesiology Clinics (in ଇଂରାଜୀ). Elsevier Health Sciences. p. e101. ISBN 978-0-323-52998-3. Archived from the original on 12 November 2022. Retrieved 3 November 2022.

[5] Noor, N; Legendre, R; Cloutet, A; Chitneni, A; Varrassi, G; Kaye, AD (2021). "A comprehensive review of remimazolam for sedation". Health psychology research. 9 (1): 24514. doi:10.52965/001c.24514. PMID 34746482.

[6] Goudra, BG; Singh, PM (July 2014). "Remimazolam: The future of its sedative potential". Saudi journal of anaesthesia. 8 (3): 388–91. doi:10.4103/1658-354X.136627. PMID 25191193.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[AHFS2022-7] "Remimazolam Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 3 November 2022.

[8] "Byfavo Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 29 May 2022. Retrieved 3 November 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]